Status:

Do Not Prescribe (DNP), Red

Decision Date:

August 2024

Comments

RED: NICE TA1048: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (decision date April 2025)

DNP: NICE TA987 for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. (Terminated appraisal) (decision date August 2024)

DNP: NICE TA1083 (Terminated appraisal) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (Decision date Aug 2025)

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again